WHIM syndrome
About
WHIM syndrome is caused by a gain-of-function mutation in the CXCR4 gene and is characterized by warts, hypogammaglobulinemia, infections, and congenital agranulocytosis. Core dilemmas: ① Neutropenia leads to repeated bacterial infections;② Hypogammaglobulinemia leads to repeated viral infections;③ Although the CXCR4 antagonist (Mavorixafor) has been approved, its long-term efficacy remains to be observed.
Features & Symptoms
- CXCR4 gene mutation
- wart, hypogammaglobulinemia
- Infection, congenital agranulocytosis
- Bone marrow granulocyte retention
Treatment Options
| Treatment | Description | Stage | Price Range |
|---|---|---|---|
| Mavorixafor（Xolremdi） | CXCR4 antagonist will be approved by the FDA for WHIM syndrome in 2024. Significantly improves neutrophil count. | FDA批准 | $400K - $800K/年 |
| G-CSF+IVIG联合 | Granulocyte colony-stimulating factor combined with intravenous immunoglobulin replacement therapy was the standard treatment before Mavorixafor was approved. | 临床应用 | $150K - $350K/年 |
| allogeneic hematopoietic stem cell transplantation | In theory, it can be cured, but patients with WHIM syndrome have limited experience in transplantation. | 个案报道 | $300K - $800K/次 |
Prognosis
Survive into adulthood, but repeated infections affect quality of life
Additional Notes
Notes: Mavorixafor treatment: Mavorixafor is the first approved treatment for WHIM syndrome, which can significantly improve neutrophil and lymphocyte counts and reduce the frequency of infections; Infection monitoring: Infection and immunoglobulin levels need to be monitored regularly, supplemented if necessary; Management of warts: HPV-related warts are common and can be treated locally with salicylic acid or imiquimod; Vaccination: Live vaccines should be avoided, inactivated vaccines can be administered normally but may not be effective; Bone marrow monitoring: Some patients with WHIM syndrome are at risk of developing myeloid leukemia and require regular blood monitoring. Exclusive service commitment: The platform will allocate a dedicated medical team to each patient to assist in dismantling and properly deploying the following precautions throughout the process. When cross-state and cross-border diagnosis and treatment projects or drugs are involved, the platform will make overall arrangements for the entire docking; for disabled and semi-disabled patient groups, the platform will provide rush-free alternative solutions (including remote consultation, door-to-door sampling, direct drug delivery in the cold chain, etc.), to ensure that patients can get the same high-quality diagnosis and treatment resources without having to travel in person.; Study phase: FDA approval. Prognosis: Survival into adulthood, but repeated infections affect quality of life.
Frequently Asked Questions
What is WHIM syndrome?
WHIM syndrome is caused by a gain-of-function mutation in the CXCR4 gene and is characterized by warts, hypogammaglobulinemia, infections, and congenital agranulocytosis. Core dilemmas: ① Neutropenia leads to repeated bacterial infections;② Hypogammaglobulinemia leads to repeated viral infections;③ Although the CXCR4 antagonist (Mavorixafor) has been approved, its long-term efficacy remains to be observed.
What are the symptoms of WHIM syndrome?
CXCR4 gene mutation,wart, hypogammaglobulinemia,Infection, congenital agranulocytosis,Bone marrow granulocyte retention
How is WHIM syndrome treated?
Mavorixafor（Xolremdi）: CXCR4 antagonist will be approved by the FDA for WHIM syndrome in 2024. Significantly improves neutrophil count.; G-CSF+IVIG联合: Granulocyte colony-stimulating factor combined with intravenous immunoglobulin replacement therapy was the standard treatment before Mavorixafor was approved.; allogeneic hematopoietic stem cell transplantation: In theory, it can be cured, but patients with WHIM syndrome have limited experience in transplantation.
What is the prognosis for WHIM syndrome?
Survive into adulthood, but repeated infections affect quality of life